Biocon Biologics launches Nepexto in Australian market

Bengaluru, July 23, 2025: Biocon Limited (NSE: BIOCON, BSE: 532523) has announced that its biosimilar arm, Biocon Biologics Ltd (BBL), has officially launched Nepexto, a biosimilar to the widely used autoimmune therapy Enbrel® (Etanercept), in the Australian market. This strategic move aims to significantly expand patient access to more affordable and high-quality treatment options for various autoimmune conditions across Australia.

Shares of Biocon were up by 1.70% at ₹393.95 as of 11:05 AM on July 23.

Collaborative Commercialisation in Australia

Biocon Biologics will commercialise Nepexto® in Australia through a partnership with Generic Health, a prominent Australian firm renowned for its portfolio of high-quality generic and prescription medicines. This collaboration leverages Generic Health’s established local presence and expertise to ensure broad reach and effective distribution of the biosimilar.

Understanding Nepexto® (Etanercept Biosimilar)

Nepexto® is a biosimilar version of Etanercept, a potent tumour necrosis factor (TNF) inhibitor. TNF is a protein that plays a key role in causing inflammation in various autoimmune diseases. By blocking TNF, Etanercept reduces inflammation and other debilitating symptoms.

Nepexto® is indicated for the treatment of several chronic inflammatory conditions, mirroring the indications of its reference product, Enbrel®. These include:

• Rheumatoid arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.
• Juvenile idiopathic arthritis: A type of arthritis that affects children.
• Psoriatic arthritis: A form of arthritis that affects some people who have psoriasis, a skin condition characterised by red patches of skin covered with silvery scales.
• Plaque psoriasis: A chronic autoimmune condition that results in scaly, itchy patches on the skin.
• Ankylosing spondylitis: A form of arthritis that primarily affects the spine, leading to severe chronic pain and discomfort.

Nepexto® secured EU marketing authorisation in 2020 and has since seen broad adoption across Europe, demonstrating its comparable efficacy and safety to the reference product. Its introduction to Australia marks a significant step in Biocon Biologics’ global expansion, particularly strengthening its footprint in the immunology therapeutic area.

“We are building on our strong European foundation to expand Nepexto® into new markets and further strengthen our immunology offering,” said a company spokesperson.

The move follows Biocon Biologics’ 2022 global acquisition and vertical integration of its biosimilars business, aimed at enabling seamless global market entry for critical biologics.

Biocon Biologics’ Global Expansion Strategy

This Australian debut aligns with Biocon Biologics’ broader global strategy, particularly following its 2022 global acquisition and vertical integration of its biosimilars business. This acquisition, which involved fully integrating the biosimilars business from its long-standing partner Viatris, was a historic milestone aimed at establishing a fully integrated, global biosimilars enterprise. The integration has allowed Biocon Biologics to have direct commercial operations in over 120 countries, enhancing its “lab to market” capabilities for critical biologics.

Biocon Biologics has embarked on a three-stage strategic journey: ‘Preserve’, ‘Consolidate’, and ‘Accelerate’. Having successfully completed the ‘Preserve’ and ‘Consolidate’ phases, including surpassing the USD 1 billion annual revenue mark in FY24, the company is now in the ‘Accelerate’ phase (from 2025 onwards). This phase focuses on launching new products in existing markets and introducing existing products, such as Nepexto®, into new territories like Australia. The overarching goal is to be among the top 3 biosimilar companies globally, expanding access to affordable, high-quality biologic medicines to millions of patients worldwide.

What Does This Mean For Investors In India?

Biocon’s launch of Nepexto® in Australia marks another step in its global biosimilar expansion, reinforcing its long-term growth potential in the immunology segment. For investors, this development carries several implications:

• Positive Signal for Growth: The move highlights Biocon Biologics’ strong execution on its global strategy. It adds a new revenue stream in a regulated market, which could support top-line growth over the medium term.
• Strengthening Global Presence: Partnering with Generic Health provides a solid commercial foothold in Australia, increasing Biocon’s visibility and reach in developed markets beyond Europe.
• Confidence Boost: The stock’s 1.7% intraday rise reflects positive market sentiment. Investors may view this as a sign that Biocon is on track with its ‘Accelerate’ phase and is capable of delivering future product launches.
• Long-Term Potential in Biosimilars: With biosimilars playing a key role in global healthcare affordability, Biocon’s growing portfolio—including Nepexto®—positions it well to tap into rising demand.
• Steady Execution Track Record: Successful product rollouts in new geographies could gradually improve margins and support rerating of the stock over time, provided execution stays consistent.

About Biocon Limited

Biocon Limited is a publicly listed biopharmaceutical company headquartered in Bengaluru, India. Through its subsidiary Biocon Biologics, it focuses on developing and marketing biosimilars across the globe. The company is listed on both the BSE (Scrip Code: 532523) and NSE (Symbol: BIOCON).

REF:https://www.bseindia.com/xml-data/corpfiling/AttachLive/aa35c41d-3db4-416a-9a02-a71bd2ca2e44.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations